On October 20, 2025 CIS BIOPHARMA AG, a company pioneering new cancer targets, reported that the company will present an abstract & poster about its lead ADC called CBO-001 at this year’s American Association for Cancer Research (AACR) (Free AACR Whitepaper) -AACR- NCI-EORTC- AACR-NCI-EORTC (Free AACR-NCI-EORTC Whitepaper) International Conference on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR) (Free ASGCT Whitepaper) (Free EORTC-NCI-AACR Whitepaper) (Press release, CIS BIOPHARMA, OCT 20, 2025, View Source [SID1234657093]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The AACR (Free AACR Whitepaper)-NCI-EORTC will be held October 22-26, 2025, at the Boston Hynes Convention Center in Boston, Massachusetts. The poster highlights preclinical data on CBO-001, a proprietary antibody-drug conjugate (ADC) developed by CIS BIOPHARMA. "We are excited to share our preclinical data at this year’s AACR (Free AACR Whitepaper)-NCI-EORTC meeting, demonstrating exceptional efficacy of our L1CAM ADC in several cancer indications, with outstanding results in small-cell lung cancer and ovarian cancer," says Dominik Brücher, Ph.D., Chief Technology Officer of CIS BIOPHARMA AG.

"The superior pre-clinical efficacy of this emerging cancer target versus standard-of-care and other emerging targets such as B7H3 and DLL3 in SCLC, positions us in a unique competitive situation, also envisioning combination strategies with these. Our overall goal with CBO-001 is to develop therapeutic options with superior overall survival for patients with SCLC, OC and other L1CAM positive malignancies."